<DOC>
	<DOCNO>NCT00800436</DOCNO>
	<brief_summary>This two-part study design select subcutaneous ( SC ) dose Herceptin result comparable exposure intravenous ( IV ) Herceptin healthy male participant HER2-positive female participant . The study also assess safety tolerability SC IV formulation . In Part 1 study , four cohort treat single dose Herceptin follow : Cohort 1 ( 6 milligram per kilogram [ mg/kg ] IV healthy male participant ) ; Cohort 2 ( 6 mg/kg IV HER2-positive female participant ) ; Cohort 3 ( 6 mg/kg SC healthy male participant ) ; Cohort 4 ( 10 mg/kg SC healthy male participant ) . An additional cohort healthy volunteer ( Cohort 5 ) open SC dose level Cohorts 3 4 result Herceptin exposures different target concentration produce single IV dose , variability pharmacokinetic ( PK ) parameter value use define target SC dose level . In Part 2 study , HER2-positive female participant receive single dose SC Herceptin dose level define Part 1 . Participants Part 1 eligible enter Part 2 provide receive second ( Part 2 ) study dose Herceptin minimum 22 day first ( Part 1 ) dose .</brief_summary>
	<brief_title>A Dose-Finding Study Subcutaneous Herceptin ( Trastuzumab ) Healthy Male Volunteers Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Females</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Healthy Participants ( Part 1 ) Males 18 45 year age Baseline leave ventricular ejection fraction ( LVEF ) great ( &gt; ) 60 percent ( % ) HER2Positive Females ( Parts 1 2 ) Females great equal ( â‰¥ ) 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 0 Previous nonmetastatic operable primary invasive HER2positive breast cancer Baseline LVEF &gt; 55 % Healthy Participants ( Part 1 ) Clinically significant abnormality laboratory test result electrocardiogram History significant allergy , gastrointestinal , renal , hepatic , cardiovascular , pulmonary disease History hypersensitivity allergic reaction , spontaneous follow drug administration History cardiac condition HER2Positive Females ( Parts 1 2 ) Metastatic disease Concurrent malignancy require therapy modality may interfere PK investigation result unexpected toxicity Use Herceptin previous 5 month Serious cardiac illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>